Reply
Michelle Martinot‐Peignoux, Tarik Asselah, Patrick Marcellin – 28 July 2011
Hot‐topic debate on kidney function: Renal‐sparing approaches are beneficial
François Durand – 27 July 2011 – Key Points
Place of liver transplantation in the treatment of hepatocellular carcinoma in the normal liver
Jan Lerut, Hynek Mergental, Delawir Kahn, Luiz Albuquerque, Juan Marrero, Jean Nicolas Vauthey, Robert J Porte – 27 July 2011
MicroRNA‐199a/b‐3p: A new star in the liver microcosmos
Christoph Roderburg, Christian Trautwein, Tom Luedde – 25 July 2011
MicroRNA‐29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression
Jian‐Hong Fang, Hui‐Chao Zhou, Chunxian Zeng, Jine Yang, Yinglin Liu, Xiuzhi Huang, Jing‐Ping Zhang, Xin‐Yuan Guan, Shi‐Mei Zhuang – 25 July 2011 – Hepatocellular carcinoma (HCC) is a highly vascularized tumor with frequent intrahepatic metastasis. Active angiogenesis and metastasis are responsible for rapid recurrence and poor survival of HCC. We previously found that microRNA‐29b (miR‐29b) down‐regulation was significantly associated with poor recurrence‐free survival of HCC patients.
Sinusoidal endothelium is essential for liver regeneration
Jennifer Gamble, Mathew Vadas, Geoffrey McCaughan – 25 July 2011
Hepatic tuberculosis in a patient treated with infliximab
Toshiyuki Morisawa, Takahisa Yoshikawa, Motoshige Nabeshima – 25 July 2011
Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review
Yun‐Fan Liaw – 25 July 2011 – This clinically relevant review focuses on recent findings concerning hepatitis B surface antigen (HBsAg) quantitation in untreated patients and treated patients with chronic hepatitis B. Recent studies and emerging data have shown that both HBsAg and hepatitis B virus (HBV) DNA levels decline during the natural course of a chronic HBV infection; they are lowest in the inactive phase, which is also characterized by the highest HBsAg/HBV DNA ratio.
Vitamin D: An innate antiviral agent suppressing hepatitis C virus in human hepatocytes
Meital Gal‐Tanamy, Larisa Bachmetov, Amiram Ravid, Ruth Koren, Arie Erman, Ran Tur‐Kaspa, Romy Zemel – 25 July 2011 – Vitamin D supplementation was reported to improve the probability of achieving a sustained virological response when combined with antiviral treatment against hepatitis C virus (HCV). Our aim was to determine the in vitro potential of vitamin D to inhibit HCV infectious virus production and explore the mechanism(s) of inhibition. Here we show that vitamin D3 remarkably inhibits HCV production in Huh7.5 hepatoma cells.